Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR

#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE

During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations. ⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM ➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum

HCQ and risk of retinopathy 👁️ DoD database HCQ 44000+ females & 10000+ males Risk retinopathy HR 1.5 Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7 No adjustment on HCQ dose @RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45

#ACR23 Abstr# 2489 I can’t wait for Phase 3 RCT results as I have many #SLE patients with refractory cutaneous lupus. Post-hoc analyses of Phase 2 RCT of Deucravacitinib showed its efficacy (CLASI-50) over PBO across all CLE subtypes @RheumNow https://t.co/G7edkAU18J

And to continue B-SAFE Clinical risk score for HCQ retinopathy 👁️ 10 years 4000+ pts, 3% retinopathy over 5yrs Predictors of HCQ retinopathy -body weight -sex -age -eGFR -weight based dose mg/kg -higher cumulative dose Risk ranges 1% to >20% @RheumNow #ACR23 ABST2453 https://t.co/h2tl6vH9M3 https://t.co/8iuRxoVaJ0

#ACR23 Abstr# 2490 Data supporting aggressive early treatment in #SLE? Multicentre open label RCT in China showed low dose MMF + Pred 0.5mg/kg/d reduced severe flare & lupus nephritis cases vs HCQ + Pred in new onset SLE with high dsDNA but w/o major organ involvement @RheumNow https://t.co/oRlgCaOvXo

#ACR23 Abstr# 2487 How to reduce PBO response in #SLE trials? Try adding low dose GC as co-primary endpoint. Interim analysis of Phase 2 RCT: SRI-4 + sustained GC dose to ≤5mg/d or ≤BL from Wk16 to 28 was met more in Ianalumab (BAFF-R-i) vs PBO (44% vs 9%) @RheumNow https://t.co/JEnMWKilR6

Rashes in Rheumatology at #ACR23 Which disease entity are these palms pathognomonic for? @RheumNow https://t.co/NmT1LTzWmm

Therapeutic Ladder for Discoid Lupus: 1. Strict🌞protection, smoking avoidance 2. Antimalarials 3. Topicals/intralesional corticosteroids, topical CNI 4. Oral steroids, retinoids, MTX, MMF 5. Thalidomide, lenalidomide 6. IVIG, JAKi, Belimumab... BUT also Anifrolumab!… https://t.co/xSw0s12Uvk https://t.co/stIJ944d9A